Skip to search boxSkip to navigationSkip to main content

Characteristics and outcomes of an international cohort of 600 000 hospitalized patients with COVID-19

  • ISARIC Clinical Characterisation Group
    ,
  • Christiana Kartsonaki(Author)
    ,
  • J. Kenneth Baillie(Author)
    ,
  • Noelia García Barrio(Author)
    ,
  • Joaquín Baruch(Author)
    ,
  • Abigail Beane(Author)
  • University of Oxford
    ,
  • University of Edinburgh, Roslin Institute
    ,
  • Royal Infirmary of Edinburgh
    ,
  • Hospital 12 de Octubre
    ,
  • University of Oxford
    ,
  • Critical Care Asia Network
Research Output:
Contribution to journal
Article
Peer-review

Open access

Publication Information

Output type

Research Output:
Contribution to journal
Article
Peer-review

Original language

English

Pages from-to (Number of pages)

Pages 355-376 (22 pages)

Journal (Volume, Issue Number)

International Journal of Epidemiology (Volume 52, Issue 2)

Publication milestones

  • Published - 01/04/2023

Publication status

Published - 01/04/2023

ISSN

0300-5771

Publication IDs

  • Scopus: 85159603496

Abstract

Background: We describe demographic features, treatments and clinical outcomes in the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) COVID-19 cohort, one of the world’s largest international, standardized data sets concerning hospitalized patients. Methods: The data set analysed includes COVID-19 patients hospitalized between January 2020 and January 2022 in 52 countries. We investigated how symptoms on admission, co-morbidities, risk factors and treatments varied by age, sex and other characteristics. We used Cox regression models to investigate associations between demographics, symptoms, co-morbidities and other factors with risk of death, admission to an intensive care unit (ICU) and invasive mechanical ventilation (IMV). Results: Data were available for 689 572 patients with laboratory-confirmed (91.1%) or clinically diagnosed (8.9%) SARS-CoV-2 infection from 52 countries. Age [adjusted hazard ratio per 10 years 1.49 (95% CI 1.48, 1.49)] and male sex [1.23 (1.21, 1.24)] were associated with a higher risk of death. Rates of admission to an ICU and use of IMV increased with age up to age 60 years then dropped. Symptoms, co-morbidities and treatments varied by age and had varied associations with clinical outcomes. The case-fatality ratio varied by country partly due to differences in the clinical characteristics of recruited patients and was on average 21.5%. Conclusions: Age was the strongest determinant of risk of death, with a ~30-fold difference between the oldest and youngest groups; each of the co-morbidities included was associated with up to an almost 2-fold increase in risk. Smoking and obesity were also associated with a higher risk of death. The size of our international database and the standardized data collection method make this study a comprehensive international description of COVID-19 clinical features. Our findings may inform strategies that involve prioritization of patients hospitalized with COVID-19 who have a higher risk of death.

Funding Details

This work was made possible by the UK Foreign, Commonwealth and Development Office; Wellcome (215091/Z/18/Z, 205228/Z/16/ Z, 220757/Z/20/Z); Bill & Melinda Gates Foundation (OPP1209135); UK Medical Research Council Clinical Research Training Fellowship (MR/V001671/1); the philanthropic support of the donors to the University of Oxford’s COVID-19 Research Response Fund; CIHR Coronavirus Rapid Research Funding Opportunity (OV2170359) and the co-ordination in Canada by Sunnybrook Research Institute; endorsement of the Irish Critical Care—Clinical Trials Group, co-ordination in Ireland by the Irish Critical Care—Clinical Trials Network at University College Dublin and funding by the Health Research Board of Ireland (CTN-2014–12); the Rapid European COVID-19 Emergency Response research (RECOVER) (H2020 project 101003589) and European Clinical Research Alliance on Infectious Diseases (ECRAID) (965313); the COVID clinical management team, AIIMS, Rishikesh, India; the COVID-19 Clinical Management team, Manipal Hospital Whitefield, Bengaluru, India; Cambridge NIHR Biomedical Research Centre; the dedication and hard work of the Groote Schuur Hospital Covid ICU Team; support by the Groote Schuur nursing and University of Cape Town registrar bodies co-ordinated by the Division of Critical Care at the University of Cape Town; the Liverpool School of Tropical Medicine and the University of Oxford; the dedication and hard work of the Norwegian SARSCoV-2 study team; the Research Council of Norway (grant no. 312780) and a philanthropic donation from Vivaldi Invest A/S owned by Jon Stephenson von Tetzchner; Imperial NIHR Biomedical Research Centre; the Comprehensive Local Research Networks of which PJMO is an NIHR Senior Investigator (NIHR201385); Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 115523 COMBACTE, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007– 2013) and EFPIA companies, in-kind contribution; the French COVID cohort (NCT04262921) is sponsored by INSERM and is funded by the REACTing (REsearch & ACtion emergING infectious diseases) consortium and by a grant of the French Ministry of Health (PHRC n 20–0424); Stiftungsfonds zur Förderung der Bekämpfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna (project no. APCOV22BGM); Italian Ministry of Health ‘Fondi Ricerca corrente–L1P6’ to IRCCS Ospedale Sacro Cuore–Don Calabria; Australian Department of Health grant (3273191); Gender Equity Strategic Fund at University of Queensland, Artificial Intelligence for Pandemics (A14PAN) at University of Queensland, the Australian Research Council Centre of Excellence for Engineered Quantum Systems (EQUS, CE170100009), the Prince Charles Hospital Foundation, Australia; grants from Instituto de Salud Carlos III, Ministerio de Ciencia, Spain; Brazil, National Council for Scientific and Technological Development (scholarship no. 303953/2018–7); the Firland Foundation, Shoreline, Washington, USA; a grant from foundation Bevordering Onderzoek Franciscus; the South Eastern Norway Health Authority and the Research Council of Norway; and preparedness work conducted by the Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection. Data and Material provision was supported by grants from the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059) and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with PHE (award no. 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award no. 200927), Liverpool Experimental Cancer Medicine Centre (grant no. C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (award no. IS-BRC-1215–20013) and NIHR Clinical Research Network providing infrastructure support.
FundersFunding numbers
Artificial Intelligence for Pandemics
-
Australian Department of Health
3273191
COVID-19 Clinical Management team
-
European Clinical Research Alliance on Infectious Diseases
965313
Groote Schuur Hospital Covid ICU Team
-
HPRU
-
Italian Ministry of Health “Fondi Ricerca corrente
-
Manipal Hospital Whitefield
-
Ministerio de Ciencia
-
NIHR Biomedical Research Centre at Imperial College London
IS-BRC-1215–20013
South Eastern Norway Health Authority and the Research Council of Norway
-
Stiftungsfonds zur Förderung der Bekämpfung der Tuberkulose und anderer Lungenkrankheiten of the City of Vienna
APCOV22BGM
foundation Bevordering Onderzoek Franciscus
-
BMGF
OPP1209135
Firland Foundation
-
WT
220757/Z/20/Z, 215091/Z/18/Z, 205228/Z/16/ Z
HRB
CTN-2014–12
H2020
101003589
SRI
-
FP7
-
EFPIA
NCT04262921
BRC
-
NIHR HPRU
-
IRSC
OV2170359
MRC
MR/V001671/1
NIHR
MC_PC_19059, CO-CIN-01
Imperial College London
200927
Oxford University
-
ARC
CE170100009
UCD
-
Inserm
-
UQ
-
PHE
200907
CNPq
303953/2018–7
Ministère des Affaires Sociales et de la Santé
PHRC n 20–0424
ISCIII
-
Norges Forskningsråd
NIHR201385, 312780
UCT
-
IMI
115523
Prince Charles Hospital Foundation
-
LECMC
C18616/A25153

Publication metrics

Metrics

Scopus
Citations

PlumX, opens in new tab

Citations
15
Captures
133

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well